22nd Century Group
Manufactures tobacco products for brands and develops FDA-authorized reduced-nicotine cigarettes.
Something off on this page? Send us feedback.
Profile
Produces cigarettes and filtered cigars for third-party brands while selling reduced-nicotine VLN and SPECTRUM research cigarettes. Most revenue comes from contract manufacturing at a single federally licensed U.S. facility, supported by nicotine-control tobacco-plant technology.
Manufactures cigarettes, filtered cigars, and other tobacco products for customer brands, while selling reduced-nicotine VLN cigarettes and SPECTRUM research cigarettes. NASCO runs an automated Mocksville facility, using conventional leaf sourced through third parties and reduced-nicotine leaf from contracted U.S. growers. Sales are primarily to U.S. customers, though contract manufacturing is offered to domestic and international partners.
Generates most revenue from contract-manufacturing agreements, with unit-based pricing and revenue recognized as products are made. Its nicotine-control technology combines licensed and owned tobacco-plant intellectual property, genetic engineering, gene editing, and plant breeding. VLN King and VLN Menthol King hold FDA modified-risk marketing orders with renewal applications under scientific review. The single leased plant supports both proprietary and contract-manufacturing revenue.
Company facts
Key statistics
Year to date −98.8% · Average volume (30d) 16.5K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$6.00 | −$15.60 | −160.0% | $7.5M | $2.9M | −61.7% | −4.64% |
| May 7, 2026Q1 FY26 | −$0.24 | −$1.01 | −322.5% | $4.6M | $4.1M | −11.0% | −11.03% |
| Mar 26, 2026Q4 FY25 | −$0.42 | −$1.18 | −180.5% | $4.1M | $3.5M | −12.7% | −18.03% |
| Nov 4, 2025Q3 FY25 | −$251.85 | −$15.89 | +93.7% | $4.2M | $4.0M | −4.5% | −1.55% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.2M | $1.5M | $1.0M | $4.1M | $2.9M | |
| Gross profit | −$609.0K | −$635.0K | −$1.1M | −$834.0K | −$636.0K | −$293.0K | |
| Operating income | −$2.6M | −$3.0M | −$3.2M | −$2.7M | −$3.0M | −$3.3M | |
| Net income | −$4.3M | −$3.4M | $5.5M | −$2.8M | −$3.3M | −$3.3M | |
| Diluted EPS | −$863.49 | −$204.12 | $6.93 | −$15.85 | −$18.08 | −$104.00 | |
| Gross margin | -26.8% | -28.5% | -70.7% | -79.6% | -15.5% | -10.2% | |
| Operating margin | -113.0% | -133.8% | -214.4% | -253.1% | -74.0% | -114.9% |
Fiscal years (4-quarter sums)FY21 $30.9M · FY22 $62.1M · FY23 −$18.5M · FY24 $11.9M · FY25 $7.0M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $6.1M · Total debt $1.3M · Total assets $26.2M · Shareholders' equity $18.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 345.1K · Float 188.2K · 54.5% free float
A split settled inside the quarter being compared, so quarter-on-quarter change is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Joseph Reda | 71.3K | 9.97% | 13G | Aug 20, 2026 |
| Schechter Jonathan | 71.3K | 9.90% | 13G | Aug 20, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Altria Group
Largest U.S. combustible rival across cigarettes and filtered cigars.
- British American Tobacco (ADR)
U.S. cigarette and tobacco incumbent through Reynolds American.
- Philip Morris International
International cigarette and smoke-free nicotine competitor.
- Perrigo
Store-brand nicotine replacement for adults trying to quit smoking.
- Pfizer
CHANTIX prescription therapy for adults seeking to quit smoking.
- Haleon (ADR)
U.S. nicotine-replacement portfolio for adults trying to quit smoking.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| 22nd Century Group | $3.22 | +1.90% | $1.1M | — | — | 0.1 | −29.9% |
| Altria Group | $68.70 | +0.09% | $114.63B | 14.5 | 11.9 | 5.2 | +1.3% |
| British American Tobacco (ADR) | $56.13 | +0.02% | $121.07B | 13.9 | — | 3.5 | −0.1% |
| Philip Morris International | $191.85 | −0.01% | $299.08B | 27.6 | 22.0 | 7.0 | +10.4% |
| Perrigo | $14.44 | −0.35% | $2.00B | — | 6.1 | 0.5 | −3.2% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Median | 20.7 | 10.8 | 3.2 | +1.9% |